A U.S. medical company has submitted approval to the U.S. Food and Drug Administration (FDA) for developing a new drug or cure for HIV, foreign media reported. The U.S. gene technology company AGT recently announced that it has developed the drug AGT103-T, which promises to cure AIDS, and submitted a clinical trial application to the U.S. Food and Drug Administration, the report said.
The new drug works to repair critical immune system damage caused by AIDS, repair assisted T-cell defects, and provide long-lasting viral control. After FDA approval, A Phase 1 clinical trial can be conducted.
The ultimate goal of the therapy is to restore the body’s natural immunity to AIDS, and the body’s immune system will treat it like any other disease.
To date, some 37.9 million people worldwide are living with HIV; In 2018, 1.7 million new HIV infections will be issued worldwide. The devastating effects of HIV/AIDS have been greatly reduced by the development and global distribution of antiretroviral drugs, but there is still a worldwide shortage of effective drugs to address HIV infection.
Jeff Galvin, chief executive of AGT, said that if the trial was successful, patients would be protected from the side effects of existing drugs and HIV would not develop into AIDS.